MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
7.90
+0.26
+3.40%
Closed 18:47 12/04 EST
OPEN
7.64
PREV CLOSE
7.64
HIGH
7.90
LOW
7.50
VOLUME
45.94K
TURNOVER
0
52 WEEK HIGH
14.42
52 WEEK LOW
6.11
MARKET CAP
761.03M
P/E (TTM)
122.48
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GYRE last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at GYRE last week (1117-1121)?
Weekly Report · 11/24 09:11
Weekly Report: what happened at GYRE last week (1110-1114)?
Weekly Report · 11/17 09:10
Noble Financial Remains a Buy on Gyre Therapeutics (GYRE)
TipRanks · 11/10 14:56
Weekly Report: what happened at GYRE last week (1103-1107)?
Weekly Report · 11/10 09:10
Gyre Therapeutics Reports Strong Q3 2025 Results
TipRanks · 11/08 04:19
Gyre Therapeutics GAAP EPS of $0.03 in-line, revenue of $30.56M misses by $2.37M
Seeking Alpha · 11/07 19:15
Strategic Advancements and Financial Growth Drive Buy Rating for Gyre Therapeutics
TipRanks · 11/07 17:05
More
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.